2025 年 7 月 25 日 ——基孔肯雅热国内情况点评 要点 事件： 2025 年 7 月，基孔肯雅热在国内外引发广泛关注。截至 7 月 23 日，佛 山全市已累计公开报告基孔肯雅热确诊病例 3645 例。其中顺德区 3317 例，较 前一日增长 383 例。国际方面，法国属地留尼汪岛约三分之一人口感染，印度、 孟加拉国等东南亚国家疫情持续扩散，法国、意大利等欧洲国家也出现输入性病 例及本土传播。世界卫生组织（WHO）警告，全球 119 个国家和地区存在病毒 传播，约 550 万人面临感染风险，可能对卫生系统造成压力。 点评： 国内暂无特效药与疫苗，防蚊灭蚊是防控核心：基孔肯雅热由基孔肯雅病毒 （CHIKV）引起，主要通过伊蚊叮咬传播，其临床特征为急性发热、剧烈关节痛 （可持续数周甚至数月）及皮疹，儿童、老人及免疫低下者风险更高。目前全球 尚无特效治疗药物，也无广泛使用的预防疫苗，临床以对症支持治疗为主，如使 用对乙酰氨基酚退烧等。防控方面，清除蚊虫孳生地、个人防蚊（如使用驱蚊液、 蚊帐）是关键措施。国内广东等地因埃及伊蚊、白纹伊蚊等广泛分布存在潜在传 播风险，需加强监测与公众教育。 血清学检测和病原学检 ...

Core Viewpoint - The epidemic of Chikungunya fever in Guangdong Province remains at a high plateau, indicating a severe situation that requires attention [1]. Summary by Sections Epidemic Situation - As of July 22, 2025, Shunde District in Foshan City reported a total of 2,934 confirmed cases of Chikungunya fever, with a significant increase of 463 cases in just one day [4][5]. - The first report of the epidemic in Shunde was on July 15, 2025, with 478 confirmed cases, showing an increase of over 2,000 cases in just over a week [4]. - The World Health Organization (WHO) reported that 119 countries and regions have identified Chikungunya virus transmission, with approximately 5.5 million people at risk globally, potentially leading to widespread outbreaks [4][5]. Companies Involved in Prevention and Detection - **Runben Co., Ltd. (润本股份)**: A leading domestic company in mosquito repellent products, with a revenue of 440 million yuan in 2024, showing a year-on-year growth of 35.4% and a gross margin of 54.2% [7]. - **Rainbow Group (彩虹集团)**: A well-known pest control company in China, offering a full range of mosquito repellent products that play a crucial role in controlling Chikungunya fever [8]. - **Shanghai Jahwa (上海家化)**: The "Liushen" brand is the top brand in China for mosquito repellent flower water, holding significant brand influence in mosquito prevention and personal care [9]. - **Longyun Group (朗云集团)**: A Hong Kong-listed company that has maintained the number one market share in pest control products for ten consecutive years, with notable products performing well during the epidemic [10]. - **Kangzhi Pharmaceutical (康芝药业)**: Offers a full range of baby and child health protection products, including disinfectants and mosquito repellents, demonstrating expertise in child health protection [11]. - **Shuoshi Gene (硕世纪录物)**: Utilizes gene sequencing technology for Chikungunya fever testing, providing precise diagnostic support for epidemic prevention [12]. - **Da'an Gene (达安基因)**: Provides nucleic acid testing kits for Chikungunya virus, leveraging extensive experience in molecular diagnostics [13]. - **Huiyu Medical (会域医学)**: A leading medical testing institution in China, employing advanced technology for accurate diagnosis of Chikungunya fever [14]. - **Wansheng Biology (万学生物)**: Offers rapid testing solutions for Chikungunya virus, focusing on point-of-care testing [16]. - **Nuo Weisha (诺唯莎)**: Combines molecular design with various heat-start technologies to enhance detection efficiency for mosquito-borne viruses [17].